Rehabilicare Names Dan W. Gladney New President and CEO.Business Editors NEW BRIGHTON New Brighton, village (1990 pop. 22,207), Ramsey co., SE Minn., a suburb of Minneapolis–Saint Paul; inc. 1891. Its manufactures include metal products, machinery, and leather. A theological seminary is there. , Minn.--(BUSINESS WIRE)--Aug. 12, 2002 Rehabilicare Inc. (Nasdaq:REHB) announced today that Dan Gladney has been appointed Rehabilicare's new Chief Executive Officer and President, and will begin full-time involvement with the Company on September 3, 2002. Mr. Gladney will also join Rehabilicare's Board of Directors. Gladney has over 24 years of management experience in the medical products industry. Prior to joining Rehabilicare, Mr. Gladney was President of Acist Medical Systems, Inc., a manufacturer of high tech cardiovascular devices. Gladney led that company from its start-up in 1996 to its sale to Bracco S.p.A. in July 2001. Prior to joining Acist Medical Systems, Gladney worked for Cardiotronics, Baxter/Endomedix, Karl Storz Endoscopy-America, and The Kendall Company. He is a director of Neurovasx, Incisive Surgical and Heartleaf Technologies. John Maley, who will step down as acting CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. but remain Chairman of Rehabilicare, stated that, "Dan Gladney's appointment as President and CEO comes at the end of an extensive search. I believe Dan's proven track record in sales, marketing and product development, plus his international experience, are just what we need to broaden the product line in our U.S. medical business, continue to support the growth of Compex in Europe, and successfully launch the Compex Sport products in the U.S. Dan is the right person to lead these three elements of our growth strategy." Rehabilicare is a leading designer, manufacturer and provider of electromedical pain management, rehabilitation rehabilitation: see physical therapy. and muscle performance enhancing products are used for clinical, sports medicine sports medicine, branch of medicine concerned with physical fitness and with the treatment and prevention of injuries and other disorders related to sports. Knee, leg, back, and shoulder injuries; stiffness and pain in joints; tendinitis; "tennis elbow"; and , home healthcare, occupational medicine and athletic applications. In April, it received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. clearance to market the Compex Sport products over-the-counter in the USA. Statements in this press release that are not historical facts are forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. All such statements are subject to risks and uncertainties, and are discussed more fully in the Company's annual report on form 10-ksb and other filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion